Welcome to C4 Therapeutics

C4 Therapeutics is harnessing the innate power of the body to control the quality of proteins within cells.  Our approach uses drugs to target disease-causing proteins for destruction.  This breakthrough technology offers many advantages for the treatment of cancer and other diseases, while avoiding traditional drug resistance.

Latest News

Publication on Degradation Technologies Licensed from Dana-Farber Cancer Institute

blue circlesCAMBRIDGE, MA March 26, 2018 - C4 Therapeutics (C4T) today announced that an independent study featuring targeted protein degradation technologies licensed by the Company from Dana-Farber Cancer Institute were published in Nature Chemical Biology. The paper (DOI: 10.1038/s41589-018-0021-8) describes a system using a degradation tag (dTAG) for proteins that is broadly applicable to target validation for drug discovery.

“Degradation has emerged as an exciting new direction for drug discovery and the dTAG system allows the rapid degradation of engineered proteins for target validation and biological investigation,” said Dr. Nathanael  read more...


The Boston Globe Names C4 Therapeutics A Top Place to Work for 2017

blue circlesCAMBRIDGE, MA November 17, 2017 - C4 Therapeutics (C4T) has been named one of the Top Places to Work in Massachusetts in the 10th annual employee-based survey project from The Boston Globe.

Top Places to Work recognizes the most admired workplaces in the state voted on by the people who know them best – their employees. The survey measures employee opinions about their company's direction, execution, management, pay and benefits, and engagement. The employers are placed into one of four groups: small, with 50 to 99 employees; medium, with 100 to 249 workers; large, with 250 to 999; and largest, with 1,000 or more.  read more...


C4 Therapeutics Appoints Ron Kaiser as Chief Financial Officer

blue circlesCAMBRIDGE, MA November 14, 2017 - C4 Therapeutics (C4T)  Ron brings to C4 Therapeutics over 35 years of executive and financial management experience, serving as a Director, CEO and CFO for public companies and venture-backed portfolio companies in the technology and life sciences industries including Sucampo Pharmaceuticals, OTG Software, Trusted Information Systems, Charmilles Technology Manufacturing Corporation, Leeco Diagnostics, Inc., Somanetics Corporation, and Photon Sources, Inc.  Ron is a Certified Board Leadership Fellow of the National Association of Corporate Directors (NACD) and holds dual BA degrees in accounting and multi-disciplinary pre-law from Michigan State University.  read more... 

What We Do

C4 Therapeutics is harnessing the innate power of the body to control the quality of proteins within cells. Our approach uses drugs to target disease-causing proteins for destruction. This breakthrough technology offers many advantages for the treatment of cancer and other diseases, while avoiding traditional drug resistance.

In June 2015, Jay Bradner, MD and co-workers at the Dana-Farber Cancer Institute, showed that derivatives of thalidomide could be used to target specific proteins for degradation. This ground breaking research, which began in 2011, is now being advanced toward clinical impact by C4 Therapeutics, which was founded in late 2015 by Dr Bradner, along with Ken Anderson, MD, Nathanael Gray PHD, and Marc Cohen.
At C4 Therapeutics, we are combining world-class expertise in medicinal chemistry, protein biochemistry, biophysics and structural biology with pharmacology and disease biology. Our approach - which is centered on the Degronimid™ platform - prizes innovative and collaborative science, both internally and externally.


Contact Us

PhmailiconTelephone:   +1  617 588 6114

Email:   C4 Therapeutics